NTRR Continues Growth Strategy With New Joint Venture
News Jul 11, 2013
With this partnership, NTRR, a rapidly growing provider of all-natural wellness solutions, is taking the next step in capturing a share of the booming $1.7 billion medical marijuana (MMJ) market forecast to reach $6 billion over the next five years.
“Vertigo Technologies’ company focus is on the entire production cycle,” NTRR CEO Sydney Jim said. “Our goal is to bring advanced technology to this burgeoning industry and achieve efficiency and quality for the products and services we deliver.”
Through its subsidiary, Cannabis Technologies, NTRR is working to help introduce the next wave of healthier, more efficient delivery systems to the ever-growing MMJ market. By providing innovative nutraceutical products and services such as new MMJ breakthroughs, Neutra Corp. plans to follow in the footsteps of other successful public companies including Cannabis Science, Inc., Medical Marijuana Inc. and Terra Tech Corp., delivering technological advancements in the cultivation and processing of cannabis in approved markets.
BioAscent Announces New CEO and Plans to Expand Discovery Services OfferingNews
BioAscent Discovery Limited appoints new CEO, Paul Smith in preparation for the expansion of companies discovery services.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018